Medicare proposes no changes for anemia drugs
Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis.
The agency, which is slated to issue a final decision on the matter in June, also said it has found no clear proof that the drugs provide clinical benefits other than increasing hemoglobin.
Endorsement of current reimbursement guidelines would benefit shares of Amgen Inc, which rakes in billions from sales of its flagship Epogen anemia drug for treatment of kidney dialysis patients.
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- Roundtable: To Arrest HAIs, Culture Trumps Campaigns
- Wanted: Nurse PhDs
- 4 Tectonic Shifts Shaking Up Healthcare
- Slideshow: Healthcare Leaders Name IT Spending Priorities
- A Fresh Look at End-of-Life Care
- 3 in 4 Patients Want E-mail Consultations
- New Orleans East Hospital opens quietly, still seeking accreditation
- CVS Ramps Up Retail Clinics with Provider Affiliations